Treatment of colon cancer with oncolytic herpes simplex virus in preclinical models

被引：0
作者：
H Yang
T Peng
J Li
Y Wang
W Zhang
P Zhang
S Peng
T Du
Y Li
Q Yan
B Liu
机构：
[1] Tongji Hospital,Department of Gastrointestinal Surgery
[2] Tongji Medical College,Department of Blood Transfusion
[3] Huazhong University of Science and Technology,Department of Plastic and Aesthetic Surgery
[4] Hubei Provincial Cooperative Innovation Center of Industrial Fermentation,Department of Immunology
[5] Hubei University of Technology,Department of Geriatric Medicine
[6] Cancer Institute and Hospital,undefined
[7] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
[8] The Third Hospital of Wuhan City,undefined
[9] Cancer Institute and Hospital,undefined
[10] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
[11] Puai Hospital of Wuhan City,undefined
[12] Tongji Medical College,undefined
[13] Huazhong University of Science and Technology,undefined
[14] School of Pharmacology,undefined
[15] Hubei University of Science and Technology,undefined
来源：
Gene Therapy | 2016年 / 23卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Cancer stem cells (CSCs), which are a rare population in any type of cancer, including colon cancer, are tumorigenic and responsible for cancer recurrence and metastasis. CSCs have been isolated from a number of different solid tumors recently, although the isolation of CSCs in colon cancer is still challenging. We cultured colon cancer cells in stem cell medium to obtain colonosphere cells. These cells possessed the characteristics of CSCs, with a high capacity of tumorigenicity, migration and invasion in vitro and in vivo. The isolation and identification of CSCs have provided new targets for the therapeutics. Oncolytic herpes simplex viruses (oHSV) are an effective strategy for killing colon cancer cells in preclinical models. Here, we examined the efficacy of an oncolytic herpes simplex virus type 2 (oHSV2) in killing colon cancer cells and colon cancer stem-like cells (CSLCs). oHSV2 was found to be highly cytotoxic to the adherent and sphere cells in vitro, and oHSV2 treatment in vivo significantly inhibited tumor growth. This study demonstrates that oHSV2 is effective against colon cancer cells and colon CSLCs and could be a promising strategy for treating colon cancer patients.
引用
收藏
页码：450 / 459
页数：9
相关论文
共 162 条
[1]  
O'Connell JB(2004)Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging J Natl Cancer Inst 96 1420-1425
[2]  
Maggard MA(2007)Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study Lancet Oncol 8 773-783
[3]  
Ko CY(2007)Cancer stem cells: models and concepts Annu Rev Med 58 267-284
[4]  
Berrino F(2008)Invincible, but not invisible: imaging approaches toward J Clin Oncol 26 2901-2910
[5]  
DeAngelis R(2012) detection of cancer stem cells Int J Cancer 131 30-40
[6]  
Sant M(2010)Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics PLoS One 5 e10277-3389
[7]  
Rosso S(2009)Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers Cancer Res 69 3382-6760
[8]  
Bielska-Lasota M(2008)Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis Clin Cancer Res 14 6751-115
[9]  
Coebergh JW(2007)CD44 is of functional importance for colorectal cancer stem cells Nature 445 111-611
[10]  
Dalerba P(2009)Identification and expansion of human colon-cancer-initiating cells Nature 457 608-1321
12345678910